From: Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events
Immune checkpoint inhibitors | Product name | Target | Approved indication by the FDA | Date of approval |
---|---|---|---|---|
Ipilimumab | Yervoy | CTLA-4 | Melanoma, renal cell carcinoma, colorectal cancer | March 2011 |
Pembrolizumab | Keytruda | PD-1 | Melanoma, non-small cell lung cancer, non-squamous cell lung cancer (with high PD-L1 expression), renal cell carcinoma, classic Hodgkin's lymphoma, gastric or gastroesophageal junction adenocarcinoma, urothelial carcinoma, cervical cancer, large B-cell lymphoma, Merkel cell carcinoma | September 2014 |
Nivolumab | Opdivo | PD-1 | Melanoma, non-small cell lung cancer, small cell lung cancer, renal cell carcinoma, Hodgkin’s lymphoma, head and neck squamous cell carcinoma, hepatocarcinoma, colorectal cancer | December 2014 |
Avelumab | Bavencio | PD-L1 | Merkel cell carcinoma, urothelial carcinoma, renal cell carcinoma | November 2015 |
Atezolizumab | Tecentriq | PD-L1 | Urothelial carcinoma, non-small cell lung cancer, breast cancer, non-squamous non-small cell lung cancer, small-cell lung cancer | May 2016 |
Durvalumab | Imfinzi | PD-L1 | Urothelial carcinoma, non-small cell lung cancer | February 2016 |
Cemiplimab | Libtayo | PD-1 | Cutaneous squamous cell carcinoma | September 2018 |